NOVEL Health Strategies has Experience of 300+ Projects on Market Access, Pricing and HEOR

Expertise Areas

US & Global Market Access Strategy

HEOR Evidence Generation Strategy

Economic Modeling for Budget Impact Analysis

Economic Modeling for Cost Effectiveness Analysis (Recent CEAs include-ALS, HCC, GI cancer, HCV, HFrEF, Rare Diseases and submissions to HTAs)

US & Global Pricing Strategy

Real-World Evidence and Observational Studies

Global Value Dossier Development (GVD/CVD); AMCP Dossier

Payer Segmentation Analysis

Medical Device Reimbursement Strategy

Rare Disease Products

Value Assessment for M&A or Licensing

Meta-Analysis (NMA, Frequentist, Bayesian, indirect comparisons)

Systematic Literature Reviews (recent SLRs include-Submission to NICE UK, IBD with Abbvie, UF with Abbvie, Movement disorders, VOD with Jazz)

References for All Recent Projects are Available Upon Request. Email us for Details or to Request for More Information.

Recent HEOR Projects

HEOR Evidence Development Strategy for Novel First in Class Product (Multiple Projects, Recent Project Rated "Phenomenal Work Product")

Systematic Review and Meta-Analysis for Anti-TNFs (Humira, Enbrel, Remicade, Cimzia etc)

Economic Modeling for Blockbuster Product (Multiple Projects)

Budget Impact Modeling for Myeloma Blockbuster Product (US Managed Care, Recent BIM Rated "Giant Leap")

GVD for Blockbuster Product (Multiple Projects)

GVD Development, CE and BIA Modeling for Asia-Pacific (For Submission to BNHI)

Comparative Effectiveness Meta-Analysis Study (w/ Johnson & Johnson, Presented at ISPOR, Abstract in Public Domain)

HTA & Guidelines Review and Strategic Implications

HEOR & Payer Publication Strategy for Blockbuster Product

HEOR Disease Landscape (Multiple Myeloma and HCV)

Full Day HEOR and Market Access Fundamentals Workshop in Paris, France (Final Feedback "Best and Easy to Understand Workshop")

Recent Market Access Projects

40 Country Pricing and Reimbursement Strategy

2020 P&R Vision for Oncology Market (Assessment Aided in Acquisition of Cancer Biotech for $2.5B)

P&R Assessment for Ten Fixed Dose Combinations

15 Country Reimbursement Strategy for Novel Medical Device Product

Value Proposition Development for Breakthrough Neurology Product (US & EU)

US & Global Market Access Strategy for Ultra Orphan Product

NPV/DCF Valuation for Neurology Product

Strategy Market Access and Pricing Ad-Boards (Recent Ad-Board Rated as "Top 3 Best Ad-Boards")

Patient Access Program Design Strategy for First-in-Class Oncology Product

Analog Analysis for Product Launch Pricing and Access Case Study

Market Access and HTA Comprehensive Landscape Assessment and Annual Tracking for Strategic Implications (Multiple Projects)

NOVEL Won Two Platinum and Bronze Medal Awards at AMCP

NOVEL's team won two Platinum and Bronze Medal Awards for Presentations at AMCP Nexus Educational Conference at Boston.

Podium & Poster Presentations at HTAi DC

At the Health Technology Assessment HTAi Annual 2014 Meeting in Washington, DC, NOVEL's team was selected for podium and poster presentations.

Top Strategy Mishaps of 2011-2012

NOVEL's team analyzed all product launches of 2011 and 2012 and developed a list of top strategy mishaps. This report also presents the lessons learned and implications for future products.

HEOR, Pricing and Marketing Strategy for Cancer Therapies

Oncology is the highest selling indication for pharmaceutical products. In a recent event NOVEL's team discussed the 10-years trends in oncology drug development.

Developing GVD for Pricing & Market Access Success

GVD is the single and central strategy resource for pricing and reimbursement of medical products. NOVEL's team recently hosted a webinar on strategies for developing GVDs.

Economic Models for HTAs, Payers and Providers

Economic models are becoming important tools for demonstrating economic value of new products. In our recent event we presented fundamentals of developing models, interactive design and easy-to-update features.